AbCellera Biologics (ABCL) Accounts Payables (2020 - 2023)

AbCellera Biologics' Accounts Payables history runs 4 years deep, the most recent figure standing at $35.7 million for Q3 2023.

• Quarterly Accounts Payables rose 38.05% year-over-year to $35.7 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $35.7 million (up 38.05% YoY) and the FY2022 annual result came in at $33.2 million, up 3.54% from the prior year.
• Accounts Payables was $35.7 million for Q3 2023 at AbCellera Biologics, down from $52.4 million in the prior quarter.
• Across five years, Accounts Payables topped out at $52.4 million in Q2 2023 and bottomed at $13.3 million in Q1 2021.
• A 4-year average of $28.1 million and a median of $25.8 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables gained 3.54% — and 2023, when it soared 114.82%.
• AbCellera Biologics' Accounts Payables stood at $20.2 million in 2020, then jumped by 58.54% to $32.0 million in 2021, then climbed by 3.54% to $33.2 million in 2022, then increased by 7.72% to $35.7 million in 2023.
• Business Quant data shows ABCL's Accounts Payables at $35.7 million in Q3 2023, $52.4 million in Q2 2023, and $31.8 million in Q1 2023.